Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program WESTON, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines, today announced that the company has...

Transpire Bio Announces Corporate Office Expansion WESTON, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases,...

Transpire Bio Strengthens Leadership Team with New Appointments to Lead Commercialization, Quality Assurance, and Manufacturing WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases,...

Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program WESTON, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines, today announced the company dosed the...